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Pseudoachondroplasia (PSACH) is an autosomal-dominant osteochondrodysplasia due to mutations in the
gene encoding cartilage oligomeric matrix protein (COMP). Clinical diagnosis of PSACH is based primarily
on family history, physical examination, and radiographic evaluation, and is sometimes extremely difficult,
particularly in adult patients. Genetic diagnosis based on DNA sequencing, on the other hand, can be
expensive, time-consuming, and intensive because COMP mutations may be scattered throughout the
gene. However, there is evidence that decreased plasma COMP concentration may serve as a diagnostic
marker in PSACH, particularly in adult patients. Here, we report the serum and/or plasma COMP
concentration-based differential diagnosis of a family with affected adult members. The mean serum
and/or plasma COMP concentrations of the three affected family members alive (0.6970.15 and/or
0.8170.08 lg/ml, respectively) were significantly lower than those of an age-compatible control group of
21 adults (1.5270.37 and/or 1.3770.36 lg/ml, respectively; Po0.0001). Bidirectional fluorescent DNA
sequencing-based genetic diagnosis of these patients revealed a heterozygous mutation for the nucleotide
change 1532A4G in exon 14 of the COMP gene, resulting in a substitution of amino acid 511 from aspartic
acid to glycine in COMP. Thus, serum and/or plasma COMP concentration may be suggested as an
additional diagnostic marker to aid clinical and radiographic findings in suspected cases of PSACH.
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Introduction
Pseudoachondroplasia (PSACH; MIM 177170) is an auto-
somal-dominant osteochondrodysplasia affecting at least 1
in 20000 individuals and is characterized by dispropor-
tionate short stature, deformity of the lower limbs, short
fingers, loose joints, and ligamentous laxity.1 –3 Other
characteristic features include normal craniofacial appear-
ance and early-onset osteoarthritis. Its radiological findings
include small, irregular epiphyses and irregular, mush-
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roomed metaphyses of all tubular bones and flattening
and/or anterior beaking of vertebrae. Adult stature has
been reported as 82–130 cm. Although the vertebral
changes resolve with age (ie, after puberty, the vertebrae
become more normal in appearance), the epiphyseal
changes of the long bones become more severe, leading
to progressive degeneration and severe osteoarthritis.
PSACH is caused exclusively by mutations in the
cartilage oligomeric matrix protein (COMP) gene located
on chromosome 19p13.1, and, to date, all cases of PSACH
have been ascribed to mutations in exons 8–19 of this
gene.4 COMP is a homopentameric glycoprotein found in
cartilage, tendon, ligament, smooth muscle, synovium,
and osteoblast.5,6 COMP is described as a key component
of the extracellular matrix (ECM) of the skeleton. COMP
binds collagen types I, II, and IX through its C-terminal
globular domain,7–9 forming a large structural network of
macromolecules in the ECM. The secretion of mutant
COMP from chondrocytes is markedly delayed, presum-
ably due to a prolonged association with chaperones in the
rough endoplasmic reticulum (rER).10 Thus, PSACH ap-
pears to be an rER storage disease most likely caused by
improper folding of mutant COMP. The growth failure of
patients with PSACH may be explained by an increased cell
death of growth plate chondrocytes.
Current clinical diagnosis of PSACH is based primarily on
family history, physical examination, and radiographic
evaluation. However, clinical presentation varies substan-
tially between individual cases and depends on the patients’
age. Most radiographic changes are not disease-specific,
leading to misdiagnosis, particularly in adult patients.11 It
has been reported that the characteristic findings of the
spine resolves with time and normalizes in adolescence,
making diagnosis even more difficult.12 In addition, radi-
ological diagnosis is more difficult in adulthood owing to
associated changes resulting from osteoarthritis.11 Genetic
diagnosis based on DNA sequencing, on the other hand, can
be expensive and labor-intensive because COMP mutations
can be scattered throughout the gene containing 19 exons.4
However, there is evidence that decreased plasma COMP
concentration may serve as a diagnostic marker in PSACH,
particularly in adult patients.12 Mabuchi et al12 presented
evidence that circulating COMP is decreased in PSACH
patients carrying COMP mutations compared with controls.
Here, we report the serum and/or plasma COMP
concentration-based differential diagnosis of a family with
affected adult members in two generations. All the three
affected members alive were adults with noncharacteristic
radiological and clinical features.
Materials and methods
Case history
The subjects are the three dwarf members (individuals II-4,
II-6, and III-1) of a family (see pedigree in Figure 1). The
grandparents of the proband (individual III-1) were first
cousins to each other. They have had five daughters, of
whom four of them were affected, and two healthy sons.
Two of the four affected daughters (individuals II-2 and II-
3) died at ages 78 and 45, respectively. Individual II-4 is one
of the two affected daughters alive. She is 80 years old,
100 cm in height, and suffers from severe osteoarthrosis.
Individual II-6, the other affected-daughter alive, on the
other hand, is 60 years old, 90 cm in height, and the
mother of the proband. She also suffers from severe
osteoarthrosis. The proband, 36 years old and 119 cm in
height, is the only daughter of individual II-6 from a
possibly consanguineous marriage to individual II-5. She is
an intelligent woman with normal craniofacial appear-
ance. A short stature, disproportionately short limbs, and
short fingers are her only known medical problems
(Figure 2). Her radiological skeletal survey showed short-
ening of long bones and widening in her epiphyses
(Figure 3). Phalanges, metacarpals, and metatarsals were
short and thick with cone-shaped epiphyses (Figure 3a and
d). Chest radiogram showed superiorly curved clavicles and
spatulate ribs with marked costochondral calcifications
(Figure 3c). Lateral radiograph of the spine revealed
straightening of dorsal kyphosis with decreased antero-
posterior diameter of the chest and small central endplate
depressions of some dorsal vertebrae (Figure 3b). There was
normal widening of the interpedicular distances from
upper to lower spine (Figure 3b). Pelvis radiogram showed
flattened, irregular, and fragmented femoral heads with
shortened necks, increased acetabular angles, and widened
symphysis pubis (Figure 3e). The skull was normal.
These adulthood findings were uncharacteristic of a
given osteochondrodysplasia, but were suggestive of
PSACH or Acromesomelic dysplasia, Maroteaux type
(AMDM, MIM 602875). The review of this family by the
European Skeletal Dysplasia Network (ESDN) supported our
diagnosis (Case number ESDN-00490) and suggested
COMP mutation analysis as the first choice of action for
the definitive diagnosis.
Figure 1 Family pedigree. Unnecessary spouses were omitted from
the original pedigree to simplify the presentation of the family. Filled
circles, pseudoachondroplasia (PSACH); unfilled circles and squares,
unaffected; (*), proband.
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Serum and/or plasma COMP assay
All women participating in this study as the control group
were selected at random (ie, in terms of any given health
condition) from the polyclinics of Pamukkale University
Hospital and gave informed written consent before blood
sampling. Selected participants of the control group were
matched to the age range of three patients analyzed for
COMP mutations in this study. Three milliliters of
peripheral blood were collected into an EDTA-containing
tube for plasma separation, and 5ml of peripheral blood
was collected into a plain tube containing no anti-
coagulant for serum separation. The blood samples were
centrifuged at 3000 g for 10min, and the plasma and serum
were carefully removed from their respective tubes and
transferred into plain polypropylene tubes. The samples
were stored at 801C until further processing.
Serum and/or plasma COMP concentrations of 3 patients
and 21 controls were analyzed on the basis of an enzyme
immunoassay kit (Wieslab, Lund, Sweden), according to
the manufacturer’s protocol and as described elsewhere.12
DNA extraction and COMP mutation detection
Genomic DNA was extracted from blood samples of all
three affected individuals, that is, II-4, II-6, and III-1, using
standard methods. Bidirectional fluorescent DNA sequen-
cing was employed to identify mutations in exons 8–19 of
the COMP gene.
Statistical analysis
Statistical analysis for serum and/or plasma COMP con-
centrations were performed using the nonparametric
Mann–Whitney’s U-test, and Po0.05 was taken as statis-
tically significant.
Results
Serum and/or plasma COMP concentrations
The mean serum and/or plasma COMP concentrations of
three affected family members alive (0.6970.15 and/or
0.8170.08 mg/ml, respectively) were significantly lower
than those of an age-compatible control group of 21
adults (1.5270.37 and/or 1.3770.36mg/ml, respectively;
Po0.0001; Table 1). There was no overlap in the distribu-
tion of serum and/or plasma COMP concentration between
PSACH patients and controls (Figure 4).
COMP mutation detection
All three affected family members were heterozygous for
the nucleotide change c.1532A4G in exon 14 of the COMP
gene (Figure 5; nucleotide numbering is according to cDNA
sequence with Genbank accession number XM_009336.
Nucleotide 1 has been counted as the first nucleotide of the
translation initiation codon). This sequence change is
predicted to result in a substitution of amino acid 511
from aspartic acid to glycine in COMP (p.Asp511Gly).
Discussion
Accurate diagnosis of a given osteochondrodysplasia is a
time-consuming and often complicated process, involving
the clinical and radiographic evaluation of the proband
and other family members. Generally, the clinical and
radiographic evaluations are used to determine a differ-
ential diagnosis before a confirmatory molecular test. This
Figure 2 Photograph of proband.
Serum/plasma COMP levels in PSACH
AC Tufan et al
1025
European Journal of Human Genetics
study aimed to test the value of serum and/or plasma
COMP concentration as a possible diagnostic marker in
differentiating PSACH from other osteochondrodysplasias
before a more expensive and labor-intensive confirmatory
molecular test.
The skeletal survey of the proband revealed a short-
limbed dwarfism with acromesomelic predominance, a
generalized epiphyseal and metaphyseal involvement, and
uncertain vertebral changes. These radiological findings
alone did not allow a clear differentiation between AMDM
and PSACH, which were thought to be the most likely
diagnoses. The suspected clinical diagnosis of PSACH in
the family was supported by decreased serum and/or
plasma COMP concentration, and, then subsequently,
confirmed by DNA sequencing of COMP and the identifi-
cation of a potential disease-causing mutation.
The heterozygous nucleotide change (c.1532A4G) in
exon 14 of the COMP gene, which is predicted to result in a
substitution of amino acid 511 from aspartic acid to
glycine has not been published previously. However, it is
likely to be the cause of proband’s PSACH since aspartic
acid 511 is a conserved amino acid in the final repeat of the
Ca2þ -binding TSP-3 (calmodulin-like) repeat region of
COMP.4 Furthermore, a mutation of aspartic acid 511 to
histidine has been reported to be pathogenic in an
unrelated patient with PSACH.13 Testing of the affected
Figure 3 Radiological skeletal survey of the proband showing shortening of long bones and widening in her epiphyses. The hands and feet were
small. Phalanges, metacarpals, and metatarsals were short and thick with cone-shaped epiphyses (a and d). The tibiae and fibulae were mildly
shortened with splayed metaphyses and epiphyses (d). The shortness of the radii and ulnae was more prominent with widened epiphyses, and mild
bowing was present in proximal radii (data not shown). Chest radiogram showed superiorly curved clavicles and spatulate ribs with marked
costochondral calcifications (c). Lateral radiograph of the spine revealed straightening of dorsal kyphosis with decreased anteroposterior diameter of
the chest, and small central endplate depressions of some dorsal vertebrae (b). There was normal widening of the interpedicular distances from upper
to lower spine (b). Pelvis radiogram showed flattened, irregular, and fragmented femoral heads with shortened necks, increased acetabular angles, and
widened symphysis pubis (e).
Table 1 COMP concentrations measured in plasma and serum
Samples Plasma COMP (mg/ml) Serum COMP (mg/ml)
Group n Age range Mean7SD Range Mean7SD Range
Control 21 24–70 1.3770.36 0.95–2.17 1.5270.37 0.97–2.35
PSACH 3 36–82 0.8170.08* 0.73–0.88 0.6970.15* 0.59–0.87
COMP, cartilage oligomeric matrix protein; PSACH, pseudoachondroplasia.
*Po0.0001.
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mother and maternal aunt of the proband, both of whom
also tested heterozygous-positive for the nucleotide change
1532A4G, is further evidence that this sequence change is
likely to be the cause of the proband’s PSACH. On the other
hand, the pedigree of this family (Figure 1) is very
interesting since the proband’s grandparents were appar-
ently phenotypically normal. Thus, one would have to
postulate significant germline mosaicism for them to have
4 of 7 children affected with an autosomal-dominant
disorder.
The diagnosis of PSACH, using DNA sequencing of
COMP, is not always easy to accomplish as the mutations
can be scattered throughout 12 exons of COMP (exons
8–19).4,14 This testing can therefore be expensive and
labor-intensive, and is offered in only a few specialized
facilities around the world. The average turnaround time
for mutation screening of the COMP gene (exons 8–19) by
DNA sequencing can be between 2–15 weeks, while the
charges from a commercial laboratory may be as high as
h1500. Serum and/or plasma COMP concentration analy-
sis, on the other hand, offers a fast (ie, results are obtained
the next day) and less expensive (ie, h15 per testing)
alternative that can aid in the selection of patients who are
suitable for a confirmatory molecular test.
The study by the manufacturer of the enzyme immu-
noassay kit for COMP found mean serum concentration of
COMP in a group of 80 unselected blood donors (age 22–
59) to be 1.3570.40 mg/ml (range: 0.99–2.54). Mabuchi
et al12 reported the mean plasma concentration of COMP
in a group of 47 control blood donors (age 0–81) as
1.4270.35 mg/ml (range: 0.85–2.24). In this study, the
mean serum COMP concentration of 21 female-control
blood donors (age 24–70) was found as 1.5270.37mg/ml
(range: 0.97–2.35), whereas the mean plasma COMP
concentration of the same control group was found as
1.3770.36 mg/ml (range: 0.95–2.17).
It has been reported that COMP levels in synovial fluid
or serum increase significantly in disease conditions, such
as rheumatoid arthritis and osteoarthritis, characterized
with cartilage destruction.15,16 On the contrary, as men-
tioned earlier, the secretion of mutant COMP from
chondrocytes is markedly delayed in PSACH. Thus, low
levels of COMP are expected to be found in serum samples
of patients with mutations in the COMP gene. Supporting
this idea are the findings by Mabuchi et al12 and this
presented study. Mabuchi et al12 reported the mean plasma
COMP concentration of six PSACH patients with COMP
mutations as 0.6270.13 mg/ml (range: 0.50–0.84), whereas
this study reports the mean serum COMP concentration of
three PSACH patients with COMP mutations as
0.6970.15 mg/ml (range: 0.59–0.87) and the mean plasma
Figure 4 Plasma (a) and serum (b) cartilage oligomeric matrix
protein (COMP) concentration distributions of pseudoachondroplasia
(PSACH) patients (light squares) compared with controls (dark
diamonds).
Figure 5 Bidirectional fluorescent DNA sequencing of exons 8–19
of the cartilage oligomeric matrix protein (COMP) gene in all three
affected family members revealed the same nucleotide change
(c.1532A4G) in exon 14, resulting in a substitution of amino acid
511 from aspartic acid to glycine in COMP (p.Asp511Gly). They were
heterozygous for the mutation. Sequence information of individuals III-
1 and II-6, together with a control, are shown in this figure. Underlined
sequences, including the nucleotide change, are detailed at the right.
Wt, wild type; Mut, mutated.
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COMP concentration of the same patients as
0.8170.08 mg/ml (range: 0.73–0.88). All these detected
decreases were statistically significant (Po0.0001). In
addition, Mabuchi et al12 reported that the same approach
also reveals significant decrease in plasma COMP levels of
multiple epiphyseal dysplasia patients carrying COMP
mutations.
In conclusion, serum and/or plasma COMP concentra-
tion analysis may be suggested as a time and cost-efficient
additional diagnostic marker to clinical and radiographic
findings in osteochondrodysplasias caused by mutations in
the COMP gene.
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